# OnCo record paper-imbrave050-lancet-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-imbrave050-lancet-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-imbrave050-lancet-2023" ;
  schema:name "IMbrave050: adjuvant atezolizumab plus bevacizumab versus active surveillance after resection or ablation of high-risk hepatocellular carcinoma"@en ;
  schema:description "A year of atezolizumab plus bevacizumab after surgery or ablation for high-risk liver cancer initially reduced recurrences, but the benefit disappeared with longer follow-up, so there is still no proven adjuvant therapy."@en ;
  schema:url <https://onco.cc/key-papers/paper-imbrave050-lancet-2023/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(23)01796-8>, <https://pubmed.ncbi.nlm.nih.gov/37871608/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(23)01796-8> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Qin S, Chen M, Cheng AL, et al." ;
  onco:cancers <https://onco.cc/cancers/hcc-early/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/bevacizumab/> ;
  onco:trials <https://onco.cc/trials/imbrave050/> ;
  onco:journals <https://onco.cc/journals/lancet/> .